Antisense Therapeutics Limited ATHJF OTC

Other OTC • Healthcare • Drug Manufacturers - Specialty & Generic • AU • USD

SharesGrow Score

37/100

0/5 Pass

SharesGrow Intrinsic Value

N/A

Negative cash flow

SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Antisense Therapeutics Limited (ATHJF) .

本页证实的标准:

VALUE (0/100, 未通过) — 综合估值评分低于60/100的通过门槛。

SharesGrow 综合评分： 35/100 其中 0/7 项标准通过。

SharesGrow 7-Criteria Score

37/100

SG Score

View full scorecard →

—

价值

N/A

No coverage

—

未來

N/A

No coverage

✗

过去

0/100

→ Income

健康

67/100

Debt-to-Equity & liquidity

→ Health

护城河

50/100

→ Income

成长

58/100

→ Income

✗

收入

10/100

→ Income

估值概览 — ATHJF

估值倍数

P/E (TTM)0.0

前瞻 P/EN/A

PEG 比率N/A

前瞻 PEGN/A

P/B 比率0.00

P/S 比率3.56

EV/EBITDA0.0

每股数据

EPS (TTM)$-0.01

每股账面价值$0.00

每股营收$0.00

每股自由现金流$0.00

收益率与内在价值

盈利收益率N/A

股息收益率0.00%

EPS：实际 vs 预期

P/E Ratio & Earnings Yield

每股收益 (EPS) 历史

Year	EPS（稀释）	营收	净利润	净利润率
2015	$0.00	$3.86M	$706.92K	18.3%
2016	$-0.01	$1M	$-2.51M	-251.4%
2017	$-0.02	$69.12K	$-2.75M	-3985.8%
2018	$-0.01	$272.42K	$-2.33M	-855.7%
2019	$-0.01	$586.79K	$-2.94M	-501.8%
2020	$-0.01	$668.43K	$-5.91M	-883.9%
2021	$-0.01	$577.76K	$-8.06M	-1395.1%
2022	$-0.01	$1.78M	$-5.81M	-326.9%
2023	$-0.02	$1.58M	$-11.38M	-720.3%
2024	$-0.01	$2.97M	$-11.92M	-401.6%